Age and frailty in COVID-19 vaccine development

Type Journal Article Author Melissa K. Andrew Author Janet E. McElhaney URL https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32481-8/abstract Publication The Lancet ISSN 0140-6736, 1474-547X Date 18/11/2020 Extra Publisher: Elsevier PMID: 33220853 Journal Abbr The Lancet DOI 10.1016/S0140-6736(20)32481-8 Library Catalog www.thelancet.com Language English Abstract Older adults, particularly those who are frail or living in long-term care facilities, have been disproportionately affected by the COVID-19 pandemic.1 Vaccines that are safe and effective in this population have been eagerly anticipated. In The Lancet, Maheshi Ramasamy and colleagues present results of the safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine in older adults (those older than 55 years).2